Primary Aldosteronism
Conditions
Keywords
diagnose, Captopril Inhibition Test (CCT)
Brief summary
Primary aldosteronism (PA) is the most common cause of secondary hypertension. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is more accurate than the traditional radioimmunoassay method in measuring aldosterone. This study aims to establish a more precise diagnostic cutoff value for the captopril stimulation test (CCT) by measuring aldosterone levels using LC-MS/MS. The investigators will combine the detection results of CCT from healthy volunteers and suspected PA patients, etc., to determine the new CCT cutoff value. The investigators expect to improve the diagnostic accuracy of PA, helping clinicians identify this curable cause of hypertension earlier and more accurately, and achieving precise treatment.
Interventions
DIAGNOSTIC_TESTCaptopril inhibition test(CCT)
The subjects are required to stop using any drugs that affect the RAAS system in advance. At 08:00 on the test day, they are to remain seated and collect baseline blood samples. Then, they are to take 25mg of captopril orally. After taking the medicine, they are to remain seated and fast for 2 hours, and then collect blood samples again at 10:00. The blood samples collected at these two time points will undergo mass spectrometry analysis to detect plasma aldosterone and renin activity, and 24-hour urine samples will be collected to measure 24-hour urine sodium and 24-hour urine potassium.
Sponsors
Peking Union Medical College Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
Normal Control Group Inclusion Criteria * Age 18-70 years old * BMI: 18.5-23.9kg/m² * Gender not restricted * Blood pressure: 100-120/60-80mmHg * No history of hypertension * No abnormal nodules found in adrenal CT * Previous blood potassium and electrocardiogram were all within normal ranges * No history of liver or kidney dysfunction, malignant tumors, metabolic diseases or cardiovascular diseases * No medication used
Exclusion criteria
* Those with a family history of hypertension or with clinical manifestations of secondary hypertension * Those who have been taking drugs that may affect the RAAS system for a long time (such as contraceptives, steroids, etc.) * Those with cardiac dysfunction or severe arrhythmia and unable to tolerate the test Patients with suspected primary aldosteronism Inclusion Criteria: * Patients with suspected primary aldosteronism in the outpatient setting * Willing to undergo 4-week spironolactone treatment and cooperate with follow-up
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Plasma Aldosterone Concentration (PAC) by LC-MS/MS before and after captopril inhibition test | Two weeks after completing the captopril inhibition test |
| Plasma Renin activity(PRA) by LC-MS/MS before and after captopril inhibition test | Two weeks after completing the captopril inhibition test |
| Aldosterone-renin ratio（ARR）by LC-MS/MS before and after captopril inhibition test | Two weeks after completing the captopril inhibition test |
Countries
China
Contacts
CONTACTTong Anli
Outcome results
None listed